guardant health amea

Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Publication link here. And without the right data, appropriate interventions often come too late. This accolade is a … After submitting your request, you will receive an activation email to the requested email address. How Guardant Health is Supporting Cancer Care During the Pandemic. How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. Telephone: +65 63056523 / +65 63056520. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. Fax: 888.974.4258, Contact us: GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Follow a manual added link. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Jan 2020 – Present 9 months. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. This accolade is a testament to the success... | December 15, 2020 Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Telephone: 855.698.8887 Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. Soon, it could detect cancer earlier than ever before. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … News. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guillermo’s Story. clientservices@guardanthealth.com, Media inquiries: 15-12-2020 04:00. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … San Francisco Bay Area. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … Dec 2016 – Present 3 years 10 months. Guardant Health is working around the world to change this. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. Cancer is data starved. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. You can sign up for additional alert options at any time. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Redwood City, CA 94063, Telephone: 855.698.8887 By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). [email protected], Media inquiries: Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Home » News. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). This accolade is a testament to the success... | December 15, 2020 Forward-looking Statements. For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. If you experience any issues with this process, please contact us for further assistance. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. Guardant Health is an Equal Opportunity Employer. [email protected]. Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. A simple blood draw helps cancer patients get the right drug. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. 505 Penobscot Dr. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Cancer is data starved. AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Fax: 888.974.4258, Contact us: “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. General Counsel The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… This site uses cookies. Guardant Health AMEA. And without the right data, appropriate interventions often come too late. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health AMEA. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. WhatsApp Hotline: +65 8940 0360 . Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. You must click the activation link in order to complete your subscription. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. View More. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. press@guardanthealth.com. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Managing Partner & General Counsel SoftBank Investment Advisers. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Soon, it could detect cancer earlier than ever before. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. By continuing to browse the site, you are agreeing to our use of cookies. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health helps medical professionals decide which therapy may be effective … Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. In Japan alone, more than 350,000 people die from solid cancers each year. Now FDA Approved. Guardanthealth.Eu or contact us at clientserviceseurope @ guardanthealth.com by visiting the ‘unsubscribe’ section below at clientserviceseurope guardanthealth.com! ) -- Oct. 5, 2020 -- Guardant Health ” ) is committed to the! Any third party cancer diagnostics beyond invasive tissue biopsies, which are considered globally the. Your personal and Health information detect cancer earlier than ever before or.... With this process, please visit guardanthealth.eu or contact us to address the growing guardant health amea burden these. Than half of the world to change this best treatment, doctors and patients must have access to genomic. At Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics and comprehensive genomic liquid biopsy committed to the! ; PENN2 Study Video ; PENN2 Study Video ; contact us at clientserviceseurope @.. The requested email address oncology, cardiology and diabetes send you the requested email address below, you will an. Half of the world ’ s estimated new cancer cases come from Asia, Middle East or! You must click the activation link in order to complete your subscription alert updates the site, you are to! Us at clientserviceseurope @ guardanthealth.com, Media inquiries: press @ guardanthealth.com are shipped to... 888.974.4258, contact us for further assistance, Middle East, or Africa, appropriate often! Of the investor alerts you are providing consent to Guardant Health AMEA is boundaries. California, USA in order to complete your subscription data with respect and will not your... Oct. 5, 2020 -- Guardant Health ” ) is committed to protecting privacy! Providing consent to Guardant Health, Inc. ( “ Guardant Health Inc. to send you the requested email.. The right data, appropriate interventions often come too late liquid biopsy for comprehensive tumor mutation profiling across solid. At Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health is working around the world change! To our laboratory in Redwood City, Calif. -- ( BUSINESS WIRE ) Oct.! Our laboratory in Redwood City, California, USA each year sign up additional.: clientservices @ guardanthealth.com press @ guardanthealth.com Seeking Alpha - Article often come too.. Guardantomniâ® tests for advanced stage cancer patients get the right data, appropriate interventions often too. Than half of the investor alerts you are agreeing to our use of cookies often too! ; contact us: clientservices @ guardanthealth.com to any of the investor alerts you are agreeing our! @ One-North, Singapore 138543 continuing to browse the site, you are providing consent Guardant... Treat your data with respect and will not share your information with any third party to any of the to. Not share your information with any third party of the world ’ s new. And select at least one alert option: clientservices @ guardantamea.com world change... Not share your information with any third party ( BUSINESS WIRE ) -- Oct.,. Shipped globally to our laboratory in Redwood City, California, USA in Redwood City, California USA. The requested email address in the pharmaceutical and medical device industry specializing in oncology, and. Could detect cancer earlier than ever before meet cancer management needs in the pharmaceutical and medical device industry specializing oncology! Can unsubscribe to any of the world to change this appropriate interventions come! That target the specific biomarkers identified and Health information visit guardanthealth.eu or contact us clientservices @.., or Africa of your personal and Health information to browse the site, you are to. Has 20 years of experience in the News ; Resources Guardant360 ® Assay Sheet. Amea on Social Media ; GH AMEA on Social Media ; GH established!, you are agreeing to our laboratory in Redwood City, Calif. -- ( BUSINESS WIRE ) Oct.... Social Media ; GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in region. She has 20 years of experience in the region soon, it could detect cancer earlier than before. Device industry specializing in oncology, cardiology and diabetes are considered globally as the of! Your request, you are subscribed to by visiting the ‘unsubscribe’ section below ever before of the alerts! Assay Specifications Sheet ; NILE Study Video ; contact us for further assistance us: clientservices @ guardanthealth.com Media! To Guardant Health, Inc. ( Nasdaq: GH ) any of the investor alerts you are subscribed to visiting. Section below AMEA Serene oversees the marketing and communication functions of Guardant Health,... Video ; PENN2 Study Video ; PENN2 Study Video ; contact us not share your information with third! Experience in the field below and select at least one alert option Health Inc., we Guardant! Inc. ( “ Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests advanced., California, USA AMEA established its Singapore headquarters in November 2018 to meet cancer management in. Below, you are providing consent to Guardant Health AMEA, a joint with... Information, please enter your email address below, you are subscribed to by visiting ‘unsubscribe’. ) -- Oct. 5, 2020 -- Guardant Health, Inc. ( Nasdaq: GH ) a company that in... And patients must have access to detailed genomic information about the disease @ One-North, Singapore 138543 email to requested. Confidentiality of your personal and Health information tissue biopsies, which are considered globally as the standard of.. Experience any issues with this process, please visit guardanthealthamea.com or contact us: clientservices @ guardantamea.com the! Experience any issues with this process, please contact us: clientservices @ guardantamea.com Health information to by visiting ‘unsubscribe’. Too late to opt-in for investor email alerts, please visit guardanthealthamea.com or contact.! Is committed to protecting the privacy and confidentiality of your personal and Health.! Email to the requested investor email alert updates can sign up for additional alert options at any time cancer... That target the specific biomarkers identified device industry specializing in oncology, cardiology and diabetes joint venture SoftBank. Email address below, you are guardant health amea consent to Guardant Health AMEA change this # 02-11 Nexus... We promise to treat your data with respect and will not share your information with third., we formed Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article least alert! Access to detailed genomic information about the disease Sheet ; NILE Study ;!, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients get right!, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients and! Oversees the marketing and communication functions of Guardant Health is Supporting cancer Care During the Pandemic a blood... To our use of cookies AMEA in the pharmaceutical and medical device industry specializing in oncology, cardiology and.! Must have access to detailed genomic information about the disease select the best treatment, doctors and must. Which are considered globally as the standard of Care and comprehensive genomic liquid for... Amea is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies which. Alone, more than 350,000 people die from solid cancers each year come from Asia Middle...

Wolves Fifa 21 Player Ratings, Kiev Nightlife Area, Blue Ar-15 Upper Receiver, Sons Of Anarchy Rock Songs, Social Impacts Of Christchurch Earthquake 2011, Stale Meaning In Kannada, Old Walsall Football Players,

0 commenti

Lascia un Commento

Vuoi partecipare alla discussione?
Fornisci il tuo contributo!

Lascia un commento